{"pub": "bbc", "url": "https://bbc.co.uk/news/health-50144742", "downloaded_at": "2019-10-24 14:02:16.198909+00:00", "title": "Cystic fibrosis drug given green light in England", "language": "en", "text": "Image copyright Getty Images\n\nA life-extending drug for cystic fibrosis will be available on the NHS in England, health bosses say.\n\nNHS England reached a deal with Orkambi manufacturers Vertex Pharmaceuticals after months of talks. Patients should be able to get the drug within 30 days.\n\nThe drug improves lung function and reduces breathing difficulties and can be given to children as young as two.\n\nThe firm wanted to charge \u00a3100,000 per patient per year but a compromise has been reached in a confidential deal.\n\nIt is understood to involve significantly less than the sum originally asked for.\n\n'Best present ever'\n\nPatients and campaigners have expressed delight at the announcement.\n\nChristina Walker said it meant her son, Luis, eight, should be on it by Christmas, calling it the \"best present ever\".\n\n\"I can't stop smiling. I'm overwhelmingly happy. It's absolutely wonderful,\" she said.\n\nMedia playback is unsupported on your device Media caption Christina Walker, whose son Luis has cystic fibrosis, tells Victoria Derbyshire: \"There will be families hugging their children\"\n\nDavid Louden, from Carlisle, said the decision would make a \"huge difference\" to his daughter, Ayda, who has cystic fibrosis.\n\nHe said the battle to get it had been \"demoralising\".\n\n\"You could see this drug with all its benefits that was just hanging there in the balance, dangling like a carrot in front of you but you couldn't access it.\"\n\nThe deal comes after the Scottish government reached an agreement with the manufacturers last month.\n\nUnder the terms of the deal both Wales and Northern Ireland can now access the drug for the same price as NHS England, but there has been no announcement over whether they will.\n\n'Good for patients and taxpayers'\n\nTwo other drugs made by Vertex - Symkevi and Kalydeco - will be made available as part of the deal.\n\nThese also treat cystic fibrosis symptoms in combination but cannot be used until a patient is 12.\n\nThe treatments do not work for all patients with cystic fibrosis - only those with certain mutations.\n\nImage caption More than 10,000 people in the UK have cystic fibrosis, which cause fatal lung damage\n\nIt is estimated about half of the 10,000 patients in the UK will benefit from these drugs.\n\nCystic fibrosis is a life-shortening genetic condition that can cause fatal lung damage.\n\nOnly about half of those with the condition live to the age of 32.\n\nNHS England chief executive Simon Stevens said the deal was \"good for patients and fair to British taxpayers\".\n\nHealth Secretary Matt Hancock described it as \"wonderful news\".", "description": "A ground-breaking drug should be available within 30 days, after the NHS and the manufacturer reach a deal.", "authors": ["Nick Triggle", "Health Correspondent"], "top_image": "https://ichef.bbci.co.uk/news/1024/branded_news/164CC/production/_106904319_gettyimages-909574832.jpg", "published_at": "2019-10-24"}